Staphylococcus aureus div1b for use as vaccine

Abstract

The invention relates to an antigenic polypeptide referred to as DivIB and variants thereof, vaccines and immunogenic compositions comprising said polypeptide and the use of the vaccines and/or immunogenic compositions in the treatment and prevention of microbial infections.

1 . A method to immunize an animal subject against a microbial infection comprising administering an immunogenic composition comprising a polypeptide selected from the group consisting of:
 i) a polypeptide encoded by a nucleotide sequence of SEQ ID NO: 1, 3 or 5, or an antigenic fragment thereof;   ii) a polypeptide encoded by a nucleotide sequence wherein said sequence is degenerate as a result of the genetic code to a nucleotide sequence of SEQ ID NO: 1, 3 or 5;   iii) a polypeptide comprising an amino acid sequence encoded by SEQ ID NO: 2, 4 or 6;   iv) a polypeptide comprising an amino acid sequence that varies from a sequence of SEQ ID NO: 2, 4 or 6 by addition deletion or substitution of at least one amino acid residue; and   v) a polypeptide comprising an amino acid sequence that is at least 85% identical to an amino acid sequence of SEQ ID NO: 2, 4 or 6.   
     
     
         2 . The method according to  claim 1  wherein said polypeptide is encoded by SEQ ID NO: 1. 
     
     
         3 . The method according to  claim 1  wherein said polypeptide comprises SEQ ID NO: 2, or an antigenic part thereof. 
     
     
         4 . The method according to  claim 1  wherein said polypeptide is encoded by SEQ ID NO: 3. 
     
     
         5 . The method according to  claim 1  wherein said polypeptide comprises SEQ ID NO: 4, or an antigenic part thereof. 
     
     
         6 . The method according to  claim 1  wherein said polypeptide is encoded by SEQ ID NO: 5. 
     
     
         7 . The method according to  claim 1  wherein said polypeptide comprises SEQ ID NO: 6, or an antigenic part thereof. 
     
     
         8 . The method according to  claim 1  wherein said immunogenic composition further comprises at least one component selected from the group consisting of: adjuvants; and carriers. 
     
     
         9 . The method according to  claim 1  wherein said microbial infection is caused by a bacterial species selected from the group consisting of:  Enterococcus faecalis, Mycobacterium tuberculosis, Streptococcus  group B,  Streptococcus pneumoniae, Helicobacter pylori, Neisseria gonorrhoea, Streptococcus  group A,  Borrelia burgdorferi, Coccidiodes immitis, Histoplasma capsulatum, Klebsiella edwardii, Neisseria meningitidis  type B,  Proteus mirabilis, Shigella flexneri, Escherichia coli, Haemophilus influenzae, Chalmydia trachomatis, Chlamydia pneumoniae, Chlamydia psittaci, Francisella tularensis, Pseudomonas aeruginosa, Bacillus anthracis, Clostridium botulinum, Yersinia pestis, Burkholderia mallei  and  B. pseudomallei.    
     
     
         10 . The method according to  claim 9  wherein said bacterial species is  Streptococcus pneumonia.    
     
     
         11 . The method according to  claim 1  wherein said immunogenic composition is adapted for administration as a nasal spray. 
     
     
         12 . The method according to  claim 1  wherein said immunogenic composition includes at least one additional anti-bacterial agent. 
     
     
         13 . The method according to  claim 12  wherein said at least one additional anti-bacterial agent is a second different immunogenic agent. 
     
     
         14 . The method according to  claim 1  wherein said method immunizes against a condition that results from a microbial infection. 
     
     
         15 . The method according to  claim 14  wherein said condition is selected from the group consisting of: tuberculosis, bacteria-associated food poisoning, blood infections, peritonitis, endocarditis, osteomyelitis, sepsis, skin disorders, meningitis, pneumonia, stomach ulcers, gonorrhoea, strep throat, streptococcal-associated toxic shock, necrotizing fasciitis, impetigo, histoplasmosis, Lyme disease, gastro-enteritis, dysentery, shigellosis and arthritis. 
     
     
         16 . A method according to  claim 1  wherein said subject is a human. 
     
     
         17 . A method according to  claim 1  wherein said subject is livestock animal. 
     
     
         18 . A method according to  claim 17  wherein said livestock animal is a caprine animal. 
     
     
         19 . A method according to  claim 18  wherein said livestock animal is a bovine animal.